The acupoint herbal plaster for the prevention and treatment of postoperative nausea and vomiting after PLIF with general anesthesia: study protocol for a multicenter randomized controlled trial

• Published in: Current controlled trials in cardiovascular medicine Vol. 22; no. 1; p. 79
• Main Authors: Xu, Huiqing, Wei, Xu, Zhang, Ranxing, Li, Ling, Zhang, Zhijun, Jia, Ruo, Zhang, Xiaofei, Gao, Xiumei, Dong, Xicheng, Pan, Junjun
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22-01-2021; BioMed Central; BMC
• Subjects: Acupoint herbal plaster; Acupressure; Acupuncture points; Anesthesiology; Antiemetics; Chinese medicine; Clinical trials; Complications; Complications and side effects; Disease prevention; General anesthesia; Hospitals; Informed consent; Laboratories; Medical personnel; Medicine, Chinese; Nausea; Postoperative nausea and vomiting; Prevention; Randomized controlled trial; Spinal fusion; Study Protocol; Surgery; Testing; Transdermal medication; Vomiting; China; Beijing China; Acupoint herbal plaster; Chinese medicine; Randomized controlled trial; Postoperative nausea and vomiting
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-021-05037-7

Postoperative nausea and vomiting (PONV) are common in posterior lumbar intervertebral fusion (PLIF) patients undergoing general anesthesia. The previous clinical observation has shown that a traditional acupoint herbal plaster (AHP) is beneficial to patients with PONV. This trial aims to assess the effect of the AHP for the prevention and treatment of PONV after PLIF in patients with general anesthesia.
A multicenter, parallel, randomized controlled trial (RCT) will be conducted. A total of 166 participants will be randomized to either a treatment group receiving an AHP or a control groups receiving an acupoint placebo plaster (APP) in a 1:1 ratio. The primary outcomes are the first occurrence and frequency of nausea and vomiting. The secondary outcomes include the severity grading of nausea and vomiting using a visual analog scale (VAS) measurement system, quality of life, and serological indicators. The safety evaluation is mainly about adverse events and skin reactions' observation. Assessments will be carried out at the baseline, day 1, and day 2 (the end of the intervention). The central randomization system in the clinical trial ( http://124.205.181.142:8082/xwtf/ ) will be used to conduct random allocation.
This scientific methodology design of the trial is expected to provide clinical evidence to support the AHP for the prevention and treatment of PONV.
This study is retrospectively registered with the Chinese Clinical Trial Registry ( http://www.chictr.org.cn ) on 19 April 2018. ID: ChiCTR1800015768.